Article
Oncology
Rohann J. M. Correa, Gerard Morton, Hans T. Chung, Chia-Lin Tseng, Patrick Cheung, William Chu, Stanley K. Liu, Merrylee McGuffin, Anam Shahid, Melanie Davidson, Ananth Ravi, Joelle Helou, Yasir Alayed, Liying Zhang, Alexandre Mamedov, Andrew Loblaw
Summary: This study compared the outcomes of two-fraction prostate SABR and two-fraction HDR monotherapy. The results showed similar rates of biochemical failure, toxicity, and quality of life between the two treatment approaches. These findings support the need for a randomized controlled trial to further evaluate these treatments.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Oncology
Maud Jaccard, Stefanie Ehrbar, Raymond Miralbell, Tobias Hagen, Nikolaos Koutsouvelis, Per Poulsen, Michel Rouzaud, Stephanie Tanadini-Lang, Pelagia Tsoutsou, Matthias Guckenberger, Thomas Zilli
Summary: The study found that the dosimetric impact of intrafraction prostate motion was minimal for target coverage during single-fraction prostate SBRT with real-time electromagnetic tracking combined with beam gating.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Kei Ito, Kentaro Taguchi, Yujiro Nakajima, Hiroaki Ogawa, Keiko Nemoto Murofushi
Summary: This study used propensity score-matched analysis to compare the pain palliation effect of stereotactic body radiotherapy (SBRT) and conventional external beam radiotherapy (cEBRT) for non-spine bone metastases. The results showed that SBRT had a significantly higher pain response rate at 3 months compared to cEBRT. This suggests that large-scale randomized controlled trials are needed to further evaluate the effectiveness of SBRT and cEBRT for painful bone metastases not involving the spine.
Article
Oncology
Megumi Uto, Kengo Ogura, Tomohiro Katagiri, Keiichi Takehana, Takashi Mizowaki
Summary: This study retrospectively analyzed treatment target changes in patients with brain metastases treated with 13-fraction SRT. The mid-treatment target volume changed by more than 20% compared to the initial target volume in nearly one-third of the lesions. The study highlights the importance of adaptive radiotherapy in monitoring target changes during fractionated stereotactic radiotherapy.
RADIATION ONCOLOGY
(2021)
Article
Oncology
Yuting Wang, Qiaoqiao Li, Li Zhang, Shiliang Liu, Jinhan Zhu, Yadi Yang, Mengzhong Liu, Yaojun Zhang, Mian Xi
Summary: This study investigates the treatment efficacy of stereotactic body radiotherapy and evaluates the influence of radiation dose on local control and survival in patients with abdominal lymph node metastases from hepatocellular carcinoma. The results show that SBRT achieves satisfactory local control and survival with a dose-response relationship between radiation dose and treatment efficacy.
Article
Medicine, General & Internal
Morgan Michalet, Ons Bettaieb, Samia Khalfi, Asma Ghorbel, Simon Valdenaire, Pierre Debuire, Norbert Ailleres, Roxana Draghici, Mailys De Meric De Bellefon, Marie Charissoux, Pierre Boisselier, Sylvain Demontoy, Alexis Marguerit, Morgane Cabaille, Marie Cantaloube, Aicha Keskes, Touria Bouhafa, Marie-Pierre Farcy-Jacquet, Pascal Fenoglietto, David Azria, Olivier Riou
Summary: Stereotactic MR-guided Radiotherapy (MRgRT) is an interesting treatment option for adrenal gland metastases (AGM). This study reviewed data from 12 consecutive patients treated with MRgRT for AGM and assessed the treatment's impact on target volume coverage, organ protection, local control, and overall survival. The results showed improved dosimetric quality and good tolerance of the treatment, with high rates of local control and overall survival. Longer follow-up is needed to evaluate late toxicities and clinical outcomes.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Yuting Wang, Qiaoqiao Li, Li Zhang, Shiliang Liu, Jinhan Zhu, Yadi Yang, Mengzhong Liu, Yaojun Zhang, Mian Xi
Summary: This study aimed to investigate the treatment efficacy of stereotactic body radiotherapy (SBRT) for abdominal lymph node metastases (LNM) from hepatocellular carcinoma (HCC) and evaluate the influence of radiation dose on local control and survival. The results showed that SBRT achieved satisfactory local control and survival with a dose-response relationship between local control and radiation dose.
Article
Oncology
Christen R. Elledge, Matthew J. Krasin, Matthew M. Ladra, Sara R. Alcorn, Peijin Han, Iris C. Gibbs, Susan M. Hiniker, Nadia N. Laack, Stephanie A. Terezakis
Summary: SBRT achieves high rates of local control in pediatric patients with inoperable metastatic nonrhabdomyosarcoma sarcomas of soft tissue and bone. Total consolidation of metastatic disease with SBRT is associated with improved progression-free survival and overall survival. SBRT is well tolerated, with a small number of patients experiencing grade 3 toxicities.
Review
Oncology
Maxime Loo, Jean-Baptiste Clavier, Justine Attal Khalifa, Elisabeth Moyal, Jonathan Khalifa
Summary: Brain metastases are a common complication for cancer patients, with stereotactic radiosurgery considered a cornerstone treatment. The ideal dose and fractionation schedule remain unknown, with ongoing debates regarding the use of hypofractionated schedules and the linear-quadratic model. Recent studies have shown the importance of radiation schedule in immunomodulatory responses. Efficacy and toxicity data suggest that hypofractionated schedules may offer benefits in terms of reducing toxicity and improving local control rates compared to single-fraction treatment.
Article
Oncology
Fabian Weykamp, Philipp Hoegen, Sebastian Regnery, Efthimios Katsigiannopulos, C. Katharina Renkamp, Kristin Lang, Laila Koenig, Elisabetta Sandrini, Eva Meixner, Carolin Rippke, Carolin Buchele, Jakob Liermann, Juergen Debus, Sebastian Klueter, Juliane Hoerner-Rieber
Summary: MR-guided SBRT is an effective and non-invasive treatment for liver metastases, with promising long-term local control. However, achieving distant tumor control still poses challenges.
Review
Oncology
Xiao-Yao Feng, Jing Li, Ao-Mei Li, Sheng-Hua Jing, Xi-Xu Zhu, Zhen Wang
Summary: This study retrospectively analyzed the safety and efficacy of SBRT for recurrent and oligometastatic STS. The results showed that SBRT is a safe and effective treatment, and histological grade influences local control and survival.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Kazuhiko Hayashi, Osamu Suzuki, Hiroya Shiomi, Hitoshi Ono, Akira Setoguchi, Masataka Nakai, Erina Nakanishi, Shotaro Tatekawa, Naoko Ose, Takero Hirata, Keisuke Tamari, Yuji Seo, Soichiro Funaki, Fumiaki Isohashi, Shinichi Shimizu, Yasushi Shintani, Kazuhiko Ogawa
Summary: This study evaluated the effectiveness and safety of CyberKnife for the treatment of metastatic lung tumors using SABR with a central high dose. The results showed that SABR with a central high dose using CyberKnife is effective in controlling local lesions with acceptable toxicity.
Article
Oncology
Julian P. Layer, Katharina Layer, Gustavo R. Sarria, Fred Roehner, Cas S. Dejonckheere, Lea L. Friker, Thomas Zeyen, David Koch, Davide Scafa, Christina Leitzen, Muemtaz Koeksal, Frederic Carsten Schmeel, Niklas Schaefer, Jennifer Landsberg, Michael Hoelzel, Ulrich Herrlinger, Matthias Schneider, Frank A. Giordano, Leonard Christopher Schmeel
Summary: This study evaluates the safety and outcome profile of five-fraction stereotactic radiotherapy (FSRT) for brain metastases (BM). It shows that FSRT is a feasible and efficient approach for both adjuvant and definitive treatment, with acceptable local control rates and comparable radiation necrosis rates.
Article
Oncology
Fabian Weykamp, Efthimios Katsigiannopulos, Lars Piskorski, Sebastian Regnery, Philipp Hoegen, Jonas Ristau, C. Katharina Renkamp, Jakob Liermann, Tobias Forster, Kristin Lang, Laila Koenig, Carolin Rippke, Carolin Buchele, Juergen Debus, Sebastian Klueter, Juliane Hoerner-Rieber
Summary: This study assessed the dosimetry benefits of stereotactic magnetic resonance (MR)-guided online adaptive radiotherapy (SMART) for liver metastases. The adapted plan showed significantly superior tumor coverage and improved sparing of organs-at-risk (OAR) compared to the predicted plan.
Article
Oncology
F. Deodato, D. Pezzulla, S. Cilla, M. Ferro, R. Giannini, C. Romano, M. Boccardi, M. Buwenge, V. Valentini, A. G. Morganti, G. Macchia
Summary: This study reports the final results of a dose-escalation study of VMAT-SRS boost in patients with spine metastases. The study found that a 12 Gy dose of SRS boost after 25 Gy to the affected and adjacent vertebrae resulted in excellent local control and survival rates without significant toxicity.
Article
Oncology
Maria Gebre-Medhin, Eva Brun, Per Engstrom, Hedda Haugen Cange, Lalle Hammarstedt-Nordenvall, Johan Reizenstein, Jan Nyman, Edvard Abel, Signe Friesland, Helena Sjodin, Henrik Carlsson, Karin Soderkvist, Marcus Thomasson, Bjorn Zackrisson, Per Nilsson
Summary: The study demonstrates that for patients with locoregionally advanced HNSCC, cisplatin is superior to cetuximab in terms of locoregional control when used in combination with radiotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Yanhong Su, Panagiotis Tsagkozis, Andri Papakonstantinou, Nicholas P. Tobin, Okan Gultekin, Anna Malmerfelt, Katrine Ingelshed, Shi Yong Neo, Johanna Lundquist, Wiem Chaabane, Maya H. Nisancioglu, Lina W. Leiss, Arne Ostman, Jonas Bergh, Saikiran Sedimbi, Kaisa Lehti, Andreas Lundqvist, Christina L. Stragliotto, Felix Haglund, Monika Ehnman
Summary: This study investigates the role of antigen-presenting cells in soft tissue sarcoma, specifically focusing on the concept of cellular cross presentation. The results suggest that direct spatial interactions between CD11c+ antigen-presenting cells and CD8+ cells are associated with an active anti-tumor immune microenvironment and favorable prognosis. Furthermore, the presence of spatial cross presentation is shown to be significantly associated with overall survival, independent of established prognostic markers like tumor grade.
Article
Oncology
Balazs Acs, Irma Fredriksson, Caroline Ronnlund, Catharina Hagerling, Anna Ehinger, Aniko Kovacs, Rasmus Roge, Jonas Bergh, Johan Hartman
Summary: The study compared ER, PR, HER2, Ki67, and grade scores among pathology departments in Sweden, revealing limited variability in ER, PR, and HER2 testing but high variability in grading and Ki67 assessment, indicating a need for new technologies. Outlier labs affected endocrine and anti-HER2 treatment rates, emphasizing the importance of monitoring biomarker expression and treatment rates to improve clinical management of breast cancer.
Article
Oncology
Carina Strell, Dick Folkvaljon, Erik Holmberg, Aglaia Schiza, Viktoria Thurfjell, Per Karlsson, Jonas Bergh, Troy Bremer, Lars A. Akslen, Fredrik Warnberg, Arne Ostman
Summary: This study reveals the potential of stromal PDGFRb expression as a biomarker for RT benefit in DCIS patients, suggesting that low PDGFRb expression is predictive of strong RT benefit for IBE risk reduction, while high PDGFRb expression is not significantly associated with risk reduction.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
R. Bradley, J. Braybrooke, R. Gray, R. K. Hills, Z. Liu, H. Pan, R. Peto, D. Dodwell, P. McGale, C. Taylor, J. Bergh, S. Swain, P. A. Francis, M. Gnant, F. Perrone, M. M. Regan
Summary: Aromatase inhibitors are more effective than tamoxifen in reducing the risk of breast cancer recurrence in premenopausal women receiving ovarian suppression. The main benefit is observed in the first 4 years of treatment, with no additional benefit or loss of benefit in the following years up to 10.
Article
Oncology
Francesco Pignatti, Ulla Wilking, Douwe Postmus, Nils Wilking, Julio Delgado, Jonas Bergh
Summary: This paper discusses the understanding and measurement of drug value in oncology from the perspectives of different decision makers, including regulators, payers, patients, and clinicians. Although a unique definition capturing the concept of value is unlikely to emerge, the importance of understanding different viewpoints and how regulators can help inform different decision makers is discussed.
NATURE REVIEWS CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
P. Schmid, J. Cortes, R. Dent, L. Pusztai, H. McArthur, S. Kummel, J. Bergh, C. Denkert, Y. H. Park, R. Hui, N. Harbeck, M. Takahashi, M. Untch, P. A. Fasching, F. Cardoso, J. Andersen, D. Patt, M. Danso, M. Ferreira, M-A Mouret-Reynier, S-A Im, J-H Ahn, M. Gion, S. Baron-Hay, J-F Boileau, Y. Ding, K. Tryfonidis, G. Aktan, V Karantza, J. O'Shaughnessy
Summary: The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery significantly prolonged event-free survival in patients with early triple-negative breast cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Caroline Boman, Luisa Edman Kessler, Jonas Bergh, Alexios Matikas, Theodoros Foukakis
Summary: Despite therapeutic advances, overall survival of metastatic breast cancer (MBC) at the population level has seen little improvement. A population-based retrospective study identified characteristics of patients with very short survival time following MBC diagnosis.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Biology
Haomin Yang, Nirmala Bhoo-Pathy, Judith S. Brand, Elham Hedayati, Felix Grassmann, Erwei Zeng, Jonas Bergh, Weiwei Bian, Jonas F. Ludvigsson, Per Hall, Kamila Czene
Summary: Breast cancer patients may have increased risks of arrhythmia, heart failure, and ischemic heart disease after treatment. Specific treatments and drugs are associated with these risks.
Review
Oncology
Evangelos Tzoras, Ioannis Zerdes, Nikos Tsiknakis, Georgios C. Manikis, Artur Mezheyeuski, Jonas Bergh, Alexios Matikas, Theodoros Foukakis
Summary: The evaluation of breast cancer immune microenvironment is important in clinical practice, but the spatiotemporal organization of the anti-breast cancer immune response is not fully explored yet. Multiplex in situ methods with spectral imaging can deconvolute the different elements of tumor immune microenvironment and provide valuable information for classification and biomarker discovery. These methods enable the simultaneous evaluation of multiple targets and characterization of spatial organization of the tumor immune microenvironment.
Article
Oncology
Mark Zupancic, Anders Nasman, Anders Berglund, Tina Dalianis, Signe Friesland
Summary: Adenoid cystic carcinoma (AdCC) is a rare heterogeneous disease that is difficult to diagnose and predict prognosis, making treatment challenging. A retrospective study on a large cohort of AdCC patients in the head and neck revealed that early disease stage and major salivary gland subsite were favorable prognostic factors, while perineural invasion and radical surgery did not significantly correlate with survival. These findings have important implications for prognostic assessment of AdCC.
Article
Oncology
Anna Embring, Eva Onjukka, Claes Mercke, Ingmar Lax, Anders Berglund, Signe Friesland
Summary: This study analyzed treatment outcomes and toxicities in 215 patients with oropharyngeal cancer who received dose-escalated radiotherapy compared to a matched cohort of patients who received standard dose radiotherapy. The results showed similar overall survival rates between the two groups, but the dose-escalated group had a higher incidence of severe toxicities, such as osteoradionecrosis and late dysphagia.
Article
Oncology
Halla Sif Olafsdottir, Emmy Dalqvist, Eva Onjukka, Fredrik Klevebro, Magnus Nilsson, Giovanna Gagliardi, Gabriella Alexandersson von Dobeln
Summary: This study aimed to analyze the impact of radiotherapy on postoperative complications in neoadjuvant chemotherapy. The results showed that the addition of radiotherapy did not increase the incidence of complications, while taxane-based chemotherapy regimens were associated with postoperative complications.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Correction
Oncology
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adria Lopez-Fernandez, Markus Jonsson, Ali Razzak, Irene Brana, Luigi De Petris, Jeffrey Yachnin, Richard D. Baird, Yohann Loriot, Christophe Massard, Patricia Martin-Romano, Frans Opdam, Richard F. Schlenk, Claudio Vernieri, Michele Masucci, Xenia Villalobos, Elena Chavarria, Judith Balmana, Giovanni Apolone, Carlos Caldas, Jonas Bergh, Ingemar Ernberg, Stefan Frohling, Elena Garralda, Claes Karlsson, Josep Tabernero, Emile Voest, Jordi Rodon, Janne Lehtio
Article
Oncology
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adria Lopez-Fernandez, Markus Jonsson, Ali Razzak, Irene Brana, Luigi De Petris, Jeffrey Yachnin, Richard D. Baird, Yohann Loriot, Christophe Massard, Patricia Martin-Romano, Frans Opdam, Richard F. Schlenk, Claudio Vernieri, Michele Masucci, Xenia Villalobos, Elena Chavarria, Judith Balmana, Giovanni Apolone, Carlos Caldas, Jonas Bergh, Ingemar Ernberg, Stefan Frohling, Elena Garralda, Claes Karlsson, Josep Tabernero, Emile Voest, Jordi Rodon, Janne Lehtio
Summary: This article presents the implementation of the Molecular Tumor Board Portal, a system that integrates and interprets genomics and clinical data to support clinical decision-making in precision oncology. The system automates the interpretation and reporting of sequencing results, reducing errors and promoting consistent decision-making and data capture. It also facilitates collaborative discussion through information-rich patient reports and interactive content.
